No quarterly revenue total was found in SIONNA THERAPEUTICS, INC.'s SEC filings.
Sionna Therapeutics, Inc. (SION) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$22.2 million. As of Jun 30, 2026 it held $63.3 million in cash and investments and $8.1 million in total debt.
Revenue
—
Net income
$-29.89M
-65.4% vs year-ago quarter
Operating cash flow
$-22.22M
-22.4% vs year-ago quarter
Free cash flow
$-22.22M
-22.4% vs year-ago quarter
EPS
$-0.66
-61.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
45.21M
+2.4% vs year-ago quarter
Net cash
$55.25M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SION (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2036042
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$32.5M | -$29.6M | -$23.6M | -$23.8M | -$21.9M |
| Net income | -$29.9M | -$26.8M | -$20.4M | -$20.3M | -$18.1M |
| Diluted EPS | -$0.66 | -$0.60 | -$0.46 | -$0.46 | -$0.41 |
| Operating cash flow | -$22.2M | -$21.8M | -$16.6M | -$15.2M | -$18.2M |
| Free cash flow | -$22.2M | -$21.8M | -$16.8M | -$15.3M | -$18.2M |
| Total assets | $283.2M | $305.0M | $326.0M | $339.3M | $352.0M |
| Total liabilities | $17.5M | $16.8M | $19.1M | $17.6M | $15.6M |
| Stockholders' equity | $265.8M | $288.2M | $306.8M | $321.7M | $336.4M |
| Cash and investments | $63.3M | $63.3M | $58.5M | $50.8M | $41.0M |
| Total debt | $8.1M | $8.4M | $8.7M | $9.0M | $9.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Sep 14, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 231 Sionna Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.